TuisBCRX • NASDAQ
add
BioCryst Pharmaceuticals Inc
Vorige sluiting
$7,49
Dagwisseling
$7,44 - $7,63
Jaarwisseling
$4,03 - $8,88
Markkapitalisasie
1,58 mjd USD
Gemiddelde volume
1,63 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Jun. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 109,33 m | 32,54% |
Bedryfskoste | 61,21 m | 20,03% |
Netto inkomste | -12,67 m | 83,17% |
Netto winsgrens | -11,59 | 87,31% |
Wins per aandeel | -0,06 | 75,00% |
EBITDA | 9,08 m | 144,74% |
Effektiewe belastingkoers | -1,38% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Jun. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 272,03 m | -33,76% |
Totale bates | 472,42 m | -10,84% |
Totale aanspreeklikheid | 948,02 m | 3,20% |
Totale ekwiteit | -475,61 m | — |
Uitstaande aandele | 206,89 m | — |
Prys om te bespreek | -3,26 | — |
Opbrengs op bates | 4,66% | — |
Opbrengs op kapitaal | 5,83% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Jun. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -12,67 m | 83,17% |
Kontant van bedrywe | -1,37 m | 92,73% |
Kontant van beleggings | -2,45 m | 87,13% |
Kontant van finansiering | -1,97 m | -106,70% |
Netto kontantverandering | -5,93 m | 32,74% |
Beskikbare kontantvloei | 28,70 m | 263,15% |
Meer oor
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China. Wikipedia
Gestig
1986
Webwerf
Werknemers
536
